TreatmentTrends: Breast Cancer Q4 2015 (US) is the second in a series of reports examining current trends in the management of advanced/metastatic breast cancer from the perspective of medical…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma and are a common reason for liver transplantation in Europe. The recent market…
European Physician and Payer Perspective on Current Mainstays and Novel Entrants in the Age of Austerity Parkinson’s disease (PD) is a debilitating chronic neurodegenerative disease affecting…
TreatmentTrends: Dry/Wet Age-Related Macular Degeneration 2015 (EU) is the fourth annual syndicated report that offers a snapshot of dry and wet age-related macular degeneration (AMD) market…
Ushering in a New Era of Cancer Immunotherapies in NSCLC, Malignant Melanoma, Renal Cell Carcinoma, and SCCHN The field of cancer immunotherapy has witnessed considerable advances over the past few…
The malignant melanoma treatment landscape is dynamic and continues to undergo significant changes. Since 2011, three immune checkpoint inhibitors and four BRAF- or MEK-targeted agents have gained…
Last Updated 15 September 2015 Ulcerative colitis (UC) affects approximately 1.25 million people across the major markets. Aminosalicylates and corticosteroids are routinely prescribed for mild…
In 2014, total sales for neuropathic pain (NP) in the seven major pharmaceutical markets under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) were estimated to be…
Outpatient parenteral antimicrobial therapy (OPAT) is a convenient mechanism for treating patients with infections that require intravenous (IV) antibiotic drugs but are clinically stable and do…
This third-time report focuses on the management of diabetic nephropathy (DN) in the United States. The U.S. market for DN drugs is poised to expand owing to the growing size of the DN patient…
The United States accounts for the single largest proportion of the global medical device market, representing approximately 40% of the estimated $400 billion (USD) global market in 2014. Its large…
Myelodysplastic syndromes (MDS) consists of a group of hematological stem cell disorders that are heterogeneous in cause and manifestations but share the common features of aberrant hematopoiesis…
Last Updated 2 November 2015 Fueled by multiple label expansions of premium-priced agents and the launch of four novel therapies, the NHL market will experience significant growth over the ten-year…
Nephrologists and endocrinologists in Europe have had the opportunity to use biosimilar erythropoiesis-stimulating agents (ESAs) and human growth hormone (hGH), respectively, for several years, but…
The past two decades have seen the arrival of revolutionary new biologic therapies for the treatment of numerous diseases, including inflammatory, hematologic, and malignant conditions. The…